×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Merck sends $60 mil Vioxx biz to DDB Needham

Published on .

Merck & Co. awarded its estimated $50 million to $60 million Vioxx account to DDB Needham Worldwide, New York. Advice & Advisors, New York, handled the non-roster shop review. The as-yet unapproved prescription drug is in a new class of pain relievers known as COX-2 inhibitors, which have no stomach side effects.

Copyright August 1998, Crain Communications Inc.

Most Popular
In this article: